Superluminal Medicines, Inc.

About Superluminal Medicines, Inc.

Superluminal Medicines is a drug discovery company focused on accelerating new possibilities in drug discovery and development. They are a passionate team of scientists and innovators dedicated to transforming how medicines are discovered.

Products & Services

Hyperloop™ Platform:Combines cutting-edge structure-based drug discovery with AI-powered computational methods and experimental validation to identify and develop small molecule therapeutics.

Pipeline:Focuses initially on GPCRs, blending scientific innovation with patient-centric precision to develop next-generation treatments for cardiometabolic diseases.

Specialties

AI/ML in drug discovery Protein dynamics Structural biology G protein-coupled receptors (GPCRs) Small molecule therapeutics Cardiometabolic diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 120000000 MR: - FA: 120 million FAN: 120000000	D: 2024-09-09 FD: 2024-09-09	7 investors
2	RT: Seed T: - FT: Seed	A: 33000000 MR: - FA: 33 million FAN: 33000000	D: 2023-08-28 FD: 2023-08-28	4 investors

Series A Latest

2024-09-09

$120.0M

7 investors (Pro only)

Seed 2023-08-28

$33.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Ajay Yekkirala

Co-founder & SVP, Head of Discovery

LinkedIn (Pro only)

A

Alix Rouault

Scientist, Biology

LinkedIn (Pro only)

C

Charles Norsigian

Staff Software Engineer

LinkedIn (Pro only)

C

Chris Oalmann

VP, Medicinal Chemistry

C

Christina Westgate

Lab Operations Manager

C

Colin Gauvin

Sr. Scientist, Structural Biology

View 35 more team members with Pro

Unlock Full Team Directory

Recent News